Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.30
>-$0.01(-0.38%)
At close: 4:00 PM EDT
$0.30
>-$0.01(-0.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.45
Previous Close$0.27
Volume109.78K
Average Volume (3M)859.21K
Market Cap
$30.86M
Enterprise Value$26.51
Total Cash (Recent Filing)$354.00K
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding103,384,010
10 Day Avg. Volume1,053,339
30 Day Avg. Volume859,212
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt relative to equity reduces near-term balance-sheet strain and gives IGC more flexibility than highly leveraged peers. This can help preserve financing capacity while the company funds clinical development, although ongoing losses could still erode that cushion.
Executive Debt ConversionConverting executive obligations into equity reduced liabilities without a cash outlay and increased stockholders’ equity. The board-approved transaction strengthens the balance sheet and demonstrates management willingness to support the company’s capital structure.
Continued Credit AccessMaintaining access to a $12 million banking facility provides funding flexibility for operations and development activities. This is important for a clinical-stage company without established product revenue, though it also highlights continued dependence on external capital.
Bears Say
Declining And Minimal RevenueVery limited and declining revenue indicates that IGC has not yet established a dependable commercial base. Without meaningful product sales, licensing income, or partnerships, the company remains reliant on advancing clinical programs before it can build durable recurring revenue.
Severe Ongoing LossesThe cost structure remains far above the current revenue base, producing substantial operating and net losses. Although losses improved from earlier periods, the magnitude of the deficit shows that IGC has not demonstrated a credible path to breakeven during continued clinical development.
Persistent Cash BurnNegative operating and free cash flow across the reported periods means IGC consumes cash rather than generating internally funded growth. Continued development therefore depends on financing, debt, or strategic transactions, creating dilution and liquidity risks if capital access weakens.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.23 and its highest was $0.45 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $30.86M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 74 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -$0.02 earnings per share for the quarter.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Overvalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 103,384,010 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IGC Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IGC Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Technical Analysis
Ownership Overview
12.65% Insiders
1.32% Mutual Funds
0.77% Other Institutional Investors
83.69% Public Companies and
Individual Investors